Bucladesine (GMP)

Bucladesine (Dibutyryl cAMP) (GMP) is a Bucladesine (HY-B0764B) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bucladesine is a membrane permeable selective activator that activates cyclic adenosine phosphate dependent protein kinase A (PKA) [1].

Product Specifications

CAS Number

[362-74-3]

Product Name Alternative

Dibutyryl cAMP (GMP) ; DBcAMP (GMP)

UNSPSC

12352005

Target

Phosphodiesterase (PDE) ; PKA

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Stem Cell/Wnt; TGF-beta/Smad

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/bucladesine-gmp.html

Smiles

O=C(CCC)O[C@H]1[C@H](N2C(N=CN=C3NC(CCC)=O)=C3N=C2)O[C@@](CO4)([H])[C@@]1([H])OP4(O)=O

Molecular Formula

C18H24N5O8P

Molecular Weight

469.39

References & Citations

[1]Sharifzadeh, M., et al., Post-training intrahippocampal infusion of nicotine-bucladesine combination causes a synergistic enhancement effect on spatial memory retention in rats. Eur J Pharmacol, 2007. 562 (3) : p. 212-20.|[2]Mafune, E., M. Takahashi, and N. Takasugi, Effect of vehicles on percutaneous absorption of bucladesine (dibutyryl cyclic AMP) in normal and damaged rat skin. Biol Pharm Bull, 1995. 18 (11) : p. 1539-43.|[3]Rundfeldt, C., et al., The stable cyclic adenosine monophosphate analogue, dibutyryl cyclo-adenosine monophosphate (bucladesine), is active in a model of acute skin inflammation. Arch Dermatol Res, 2012.|[4]Shimojo M, et al. The cholinergic gene locus is coordinately regulated by protein kinase A II in PC12 cells. J Neurochem. 1998 Sep;71 (3) :1118-26.|[5]Salehi F, et al. Effect of bucladesine, pentoxifylline, and H-89 as cyclic adenosine monophosphate analog, phosphodiesterase, and protein kinase A inhibitor on acute pain. Fundam Clin Pharmacol. 2017 Aug;31 (4) :411-419.